Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ORAI1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ORAI1 Recombinant Protein / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ORAI1 Products |
| Gene Delivery | ORAI1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High-titer, mycoplasma free. |
View ORAI1 Products |
| Benchmark Ab | Anti-ORAI1 Recombinant Antibody Recombinant positive control for FACS and functional blocking assays. |
View ORAI1 Products |
| Validator | ORAI1 siRNA Set For knockdown verification in primary cells and cell lines. |
View ORAI1 Products |
| Related Target A | STIM1 Essential ER calcium sensor that binds and activates ORAI1 channel pore. |
View STIM1 Products |
| Related Target B | STIM2 Feedback regulator of store-operated calcium entry (SOCE) active at resting ER calcium levels. |
View STIM2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass transmembrane conformation preservation | Lentivirus for Stable Cell Line development to maintain native 4-transmembrane structure. |
| Selectivity screening against ORAI2/ORAI3 | Homolog panel proteins and custom cell lines strictly verified by sequence and mass spec. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for target-specific knockdown verification. |
Live ORAI1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ORAI1 therapeutics is intensifying, with major players shifting focus from non-selective calcium channel blockers to highly selective small molecule inhibitors and monoclonal antibodies. As first-generation therapies for acute pancreatitis and plaque psoriasis reach late-stage clinical trials, the next wave of R&D is targeting downstream store-operated calcium entry (SOCE) disruption in oncology and severe pulmonary inflammation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Inhibitors) | CalciMedica, Rhizen Pharmaceuticals | Acute Pancreatitis, ARDS, AKI | Calcium Flux/FLIPR Assay (Need high-titer Lentivirus for stable cell lines) |
| Monoclonal Antibody | Academic Institutions, Biotech Startups | Autoimmune Diseases, Solid Tumors | Conformational Binding (Need native-state cell line validation) |
| Combination / Pathway Blockers | Translational Research Labs | Plaque Psoriasis, Rheumatoid Arthritis | Selectivity Assay (Need ORAI1/2/3 and STIM1/2 panel reagents) |